Antiplatelet agents for the treatment of deep venous thrombosis

Flumignan, Carolina Dutra Queiroz; Nakano, Luis Cu; Baptista-Silva, Jose CC; Flumignan, Ronald Lg

doi:10.1002/14651858.cd012369.pub2

Cited by 13 publications

(8 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides anticoagulation, we found that antiplatelet agents and statin could also protect patients from hospital-acquired VTE. Platelet activation also plays a role in the pathogenesis of venous thrombosis [ 19 , 20 ]. Statin, which is primarily applied for reducing cholesterol, has also been demonstrated to be effective to reduce the risk of VTE in several studies.…”

Section: Discussionmentioning

confidence: 99%

Nomogram for hospital-acquired venous thromboembolism among patients with cardiovascular diseases

Luo,

Li,

Zhao

et al. 2024

Thrombosis J

View full text Add to dashboard Cite

Background Identifying venous thromboembolism (VTE) is challenging for patients with cardiovascular diseases due to similar clinical presentation. Most hospital-acquired VTE events are preventable, whereas the implementation of VTE prophylaxis in clinical practice is far from sufficient. There is a lack of hospital-acquired VTE prediction models tailored specifically designed for patients with cardiovascular diseases. We aimed to develop a nomogram predicting hospital-acquired VTE specifically for patients with cardiovascular diseases. Material and methods Consecutive patients with cardiovascular diseases admitted to internal medicine of Fuwai hospital between September 2020 and August 2021 were included. Univariable and multivariable logistic regression were applied to identify risk factors of hospital-acquired VTE. A nomogram was constructed according to multivariable logistic regression, and internally validated by bootstrapping. Results A total of 27,235 patients were included. During a median hospitalization of four days, 154 (0.57%) patients developed hospital-acquired VTE. Multivariable logistic regression identified that female sex, age, infection, pulmonary hypertension, obstructive sleep apnea, acute coronary syndrome, cardiomyopathy, heart failure, immobility, central venous catheter, intra-aortic balloon pump and anticoagulation were independently associated with hospital-acquired VTE. The nomogram was constructed with high accuracy in both the training set and validation (concordance index 0.865 in the training set, and 0.864 in validation), which was further confirmed in calibration. Compared to Padua model, the Fuwai model demonstrated significantly better discrimination ability (area under curve 0.865 vs. 0.786, net reclassification index 0.052, 95% confidence interval 0.012–0.091, P = 0.009; integrated discrimination index 0.020, 95% confidence interval 0.001–0.039, P = 0.051). Conclusion The incidence of hospital-acquired VTE in patients with cardiovascular diseases is relatively low. The nomogram exhibits high accuracy in predicting hospital-acquired VTE in patients with cardiovascular diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Nomogram for hospital-acquired venous thromboembolism among patients with cardiovascular diseases

Luo,

Li,

Zhao

et al. 2024

Thrombosis J

View full text Add to dashboard Cite

show abstract

“…We considered cases of acute DVT if they were treated within 21 days of developing symptoms. [7,8] Chronic DVT was considered in those patients who were treated after 21 days.…”

Section: Methodsmentioning

confidence: 99%

“…This related group of signs and symptoms is named post-thrombotic syndrome (PTS) and can occur after the DVT event with increasing frequency over time in up to 50% to 75% of DVT cases. [1,3,[6][7][8] Venous injuries, which can occur after a thrombosis, can also increase the rate of new thrombotic occurrences and worsen PTS.…”

Section: Introductionmentioning

confidence: 99%

Stenting or angioplasty for the treatment of deep vein thrombosis: Systematic review and meta-analysis of randomized controlled trials

et al. 2023

View full text Add to dashboard Cite

Background: Although the cornerstone treatment for deep vein thrombosis (DVT) remains anticoagulation, clinicians perform stenting or angioplasty (SA) in particular patients. To assess the effects of SA in this setting, we performed a systematic review of randomized controlled trials.Methods: Based on the Cochrane standards, we searched the Cochrane CENTRAL, MEDLINE, Embase, CINAHL, LILACS and IBECS databases, and trial registries. Our primary outcomes were post-thrombotic syndrome (PTS), venous thromboembolism (VTE) and all-cause mortality.Results: We included 7 randomized controlled trial (1485 participants). There was no clinically significant difference between SA and best medical practice (BMP) for the additional treatment of acute DVT regarding PTS (standardized mean difference −7.87, 95% confidence interval [CI] −12.13 to −3.61; very low-certainty) and VTE (risk ratio [RR] 1.19, 95% CI 0.28-5.07, very low-certainty), and no deaths. Compared to BMP, the SA plus BMP and thrombolysis results in little to no difference in PTS (mean difference [MD] −1.07, 95% CI −1.12 to −1.02, moderate-certainty), VTE (RR 1.48, 95% CI 0.95-2.31, low-certainty), and mortality (RR 0.92, 95% CI 0.34-2.52, low-certainty). There was no clinical difference between stenting and BMP for chronic DVT regarding PTS (MD 2.73, 95% CI −2.10 to 7.56, very low certainty) and no VTE and death events.Conclusions: SA results in little to no difference in PTS, VTE and mortality in acute DVT compared to BMP. The evidence regarding SA in chronic DVT and whether SA, compared to BMP and thrombolysis, decreases PTS and VTE in acute DVT is uncertain. Open Science Framework (osf.io/f2dm6

show abstract

“…It is recently discovered that P-selectin expression in platelets is elevated during the development of many epileptic cases, , leading to higher risk of VTE, several times that of healthy people. In fact, increasing research works are pointing to profound involvement of platelet and platelet surface proteins in the whole process of epileptic pathology. , Moreover, therapy may intervene in a complicated way in this neuron–platelet cross-talk. , This may explain why, in some cases, administration of therapy can lead to higher risk of VTE. , Therefore, to avoid a complication as lethal and unfortunate as VTE, it is essential to establish new VTE risk-evaluating assays using effective markers such as P-selectin, so that a tighter control of VTE risk during therapy can be achieved.…”

Section: Introductionmentioning

confidence: 99%

Photosensitive Peptide Enabling Molecular Recognition Tandem Covalent Biosensing for Evaluating and Preventing Venous Thromboembolism in Dravet Syndrome

Ding,

Hou,

et al. 2023

Anal. Chem.

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a complication of Dravet syndrome, accounting for many unexpected deaths. To control VTE more tightly and to prevent such tragedies, a reliable and low-cost risk evaluation assay is urgently needed, so that the daily routine of VTE risk evaluation can be established. In this work, we have developed such an assay combining the photocatalytic activity of Bengal red to trigger the target-specific self-splicing of a peptide probe and subsequent cross-linking with P-selectin. Following this protocol, a robust and one-step detection can be achieved, without using any costly enzymes, antibodies, or nanomaterials, but the same level of sensitivity and robustness can be attained. Specifically, the effect of epilepsy on elevating platelet P-selectin can be observed by using the proposed assay. This may in the near future promise a new method for evaluating the side effects of P-selectin through relatively noninvasive peripheral blood sampling.

show abstract

Antiplatelet agents for the treatment of deep venous thrombosis

Cited by 13 publications

References 81 publications

Nomogram for hospital-acquired venous thromboembolism among patients with cardiovascular diseases

Nomogram for hospital-acquired venous thromboembolism among patients with cardiovascular diseases

Stenting or angioplasty for the treatment of deep vein thrombosis: Systematic review and meta-analysis of randomized controlled trials

Photosensitive Peptide Enabling Molecular Recognition Tandem Covalent Biosensing for Evaluating and Preventing Venous Thromboembolism in Dravet Syndrome

Contact Info

Product

Resources

About